Axon Enterprise, Inc. (NASDAQ:AXON) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Axon Enterprise, Inc. (NASDAQ:AXON) have earned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $604.67.

A number of equities research analysts recently commented on AXON shares. Barclays restated a “hold” rating on shares of Axon Enterprise in a report on Monday, March 10th. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. Craig Hallum lowered shares of Axon Enterprise from a “buy” rating to a “cautious” rating in a report on Monday, March 10th. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Finally, TD Cowen started coverage on shares of Axon Enterprise in a report on Wednesday, January 8th. They set a “buy” rating and a $700.00 price objective on the stock.

Axon Enterprise Trading Up 4.1 %

Shares of NASDAQ AXON opened at $556.26 on Friday. The company’s fifty day moving average is $593.42 and its 200-day moving average is $535.46. The stock has a market cap of $42.62 billion, a price-to-earnings ratio of 143.74, a P/E/G ratio of 5.17 and a beta of 1.12. Axon Enterprise has a twelve month low of $273.52 and a twelve month high of $715.99. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Insider Activity

In related news, Director Michael Garnreiter sold 1,000 shares of Axon Enterprise stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $639.69, for a total transaction of $639,690.00. Following the completion of the sale, the director now owns 24,259 shares of the company’s stock, valued at approximately $15,518,239.71. The trade was a 3.96 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of Axon Enterprise stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total transaction of $271,831.50. Following the sale, the director now directly owns 6,929 shares of the company’s stock, valued at $4,185,601.03. The trade was a 6.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,146 shares of company stock valued at $3,262,847 in the last quarter. Company insiders own 6.10% of the company’s stock.

Institutional Trading of Axon Enterprise

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Asset Dedication LLC boosted its holdings in shares of Axon Enterprise by 11.3% during the 4th quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company’s stock worth $106,000 after buying an additional 18 shares during the period. Bleakley Financial Group LLC boosted its holdings in Axon Enterprise by 1.3% in the 4th quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company’s stock valued at $908,000 after purchasing an additional 20 shares during the period. Venturi Wealth Management LLC boosted its holdings in Axon Enterprise by 2.7% in the 4th quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company’s stock valued at $477,000 after purchasing an additional 21 shares during the period. Insigneo Advisory Services LLC boosted its holdings in Axon Enterprise by 1.4% in the 3rd quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock valued at $627,000 after purchasing an additional 22 shares during the period. Finally, Beacon Pointe Advisors LLC boosted its holdings in Axon Enterprise by 2.6% in the 4th quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company’s stock valued at $513,000 after purchasing an additional 22 shares during the period. Institutional investors own 79.08% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.